Amdocs Limited (DOX) Market Cap & Valuation Ratios
Amdocs Limited (DOX) has a market cap of $6.8B, a trailing P/E of 12.4 and a price-to-sales ratio of 1.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DOXAmdocs LimitedFollow DOX — free
—
Price chart with a free account
- Market cap
- 6.8B
- P/E TTM
- 12.4
- Dividend yield
- 3.3%
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Peers
software - infrastructure · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| DOX | 6.8 | 12.4 | 1.5 | 7.7 | 9.5% | +0.1% | 16% | 16% |
| DBX | 8.5 | 19.4 | 4.2 | 12.9 | 11.2% | 0.0% | 27% | 290% |
| ZETA | 8.5 | — | 5.4 | 78.1 | 2.4% | +36% | 2% | 3% |
| S | 8.4 | — | 7.0 | — | 0.4% | +21% | -29% | -26% |
| QLYS | 7.5 | 37.5 | 10.3 | 28.5 | 4.2% | +10% | 34% | 61% |
| PATH | 7.4 | 21.1 | 3.5 | 34.0 | 4.9% | +15% | 9% | 10% |
| WEX | 6.7 | 19.7 | 2.1 | 5.7 | 1.6% | +7% | 25% | 9% |
| BOX | 5.9 | 63.5 | 4.8 | 38.6 | 5.9% | +10% | 9% | — |
| ACIW | 5.6 | 25.6 | 3.5 | 14.4 | 5.0% | +7% | 19% | 12% |
| VRNS | 5.6 | — | 7.9 | — | 2.1% | +16% | -22% | -23% |
| MBGL | 5.5 | — | — | — | — | — | 18% | — |
| Median of these 10 | 23.4 | 4.8 | 28.5 | 4.2% | +10% | 13% | 10% |
P/E 12.4 vs. a peer median of 23.4; EV/Sales 1.5 vs. 4.8. DOX's own P/E sits at the 5th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesZETA and S and VRNS and MBGL have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Amdocs Limited — questions
- What is Amdocs Limited's market cap?
- $6.8B.
- What is Amdocs Limited's P/E ratio?
- 12.4 on trailing twelve-month earnings to 2026-06-30.
- What is Amdocs Limited's price-to-sales ratio?
- 1.5.
Every figure on this page comes from Amdocs Limited's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.